2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 322

The Activating Patients at Risk for Osteoporosis Study: A Randomized Trial within the Global Longitudinal Study of Osteoporosis in Women Cohort

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 449

the Animated Activity Questionnaire to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis: Reliability, Responsiveness, and Interpretation

Quality Measures and Quality of Care - ARHP Poster

9:00AM-11:00AM: Abstract Number: 165

The Apparent Diffusion Coefficient As a Quantitative Imaging Biomarker of Therapeutic Response in Enthesitis-Related Arthritis

Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

9:00AM-11:00AM: Abstract Number: 515

The Association of Body Mass Index with the Severity of Magnetic Resonance Imaging-Detected Inflammation at Presentation; Opposite Effects in Early Rheumatoid Arthritis Compared to Other Arthritides and an Asymptomatic Population

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 359

The Association of Scheuermann’s Disease with Osteoporotic Vertebral Fracture Risk

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 314

The Clinical Efficacy and Safety of the Gumiganhwal-Tang in Knee Osteoarthritis: A Phase II Randomized Double Blind Placebo Controlled Study

Osteoarthritis – Clinical Aspects - Poster I

9:00AM-11:00AM: Abstract Number: 607

The Clinical Response to Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) According to Gender in a French-Canadian Population with Rheumatoid Arthritis (RA)

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 532

The DAS28 Score May Misread Disease Activity in Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 711

The Diagnostic Value of the Symptom of Inflammatory Back Pain in the Rheumatology Setting

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 854

The Ducas: Proposal for a Digital Ulcer Assessment Score in Scleroderma

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

9:00AM-11:00AM: Abstract Number: 754

The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 361

The Effect of Immunosuppressive and Antiresorptive Therapy on Bone Mineral Density in Lung Transplant Patients

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 217

The Effect of Regular Treatment on Disability in a Cohort of Patients with Gout.

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 114

The Effect of Triage Assessments on Identifying Inflammatory Arthritis and Reducing Rheumatology Wait Times in Ontario

Health Services Research - ARHP Poster

9:00AM-11:00AM: Abstract Number: 452

The Efficacy of Motivational Counselling and SMS-Reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial

Quality Measures and Quality of Care - ARHP Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].